Dose adjustment in renal impairment
Dose adjustment may be needed in kidney disease.
Leaflet FRAXODI 11400UI AFXa/0.6ml 11400 uiAXa / 0.6ml solution for injection
- Product code:
- W42335002
- Quantity:
- 10
- Indicated for:
- prevention and treatment of thromboembolism
- Route of administration:
- injectable
- Substance:
- nadroparin (anticoagulant)
- ATC
- B01AB06 — Blood and blood forming organs | Antithrombotic agents | Antithrombotic agents | Heparin group
Precautions:
Major drug interactions
This medicine may have important interactions with other medicines.
Additional monitoring
This medicine is subject to additional monitoring.
Breastfeeding warning
Use during breastfeeding only on medical advice.
Pregnancy warning
Use during pregnancy only on medical advice.
Bleeding risk
This medicine may increase the risk of bleeding.
Nadroparin is a low molecular weight heparin anticoagulant used for the prevention and treatment of deep vein thrombosis and pulmonary embolism. It works by inhibiting factor Xa, preventing the formation of blood clots.
The medication is administered via subcutaneous injection, usually once or twice daily, with the dose adjusted based on the patient's weight and therapeutic indication. Common side effects include bleeding, bruising at the injection site, and thrombocytopenia.
Nadroparin is contraindicated in patients with active bleeding, heparin-induced thrombocytopenia, or hypersensitivity to the active substance. Its use also requires careful monitoring to prevent hemorrhagic complications.
This medication is an effective option for the prevention and treatment of thromboembolic complications, helping to reduce the risk of severe cardiovascular events.
The medication is administered via subcutaneous injection, usually once or twice daily, with the dose adjusted based on the patient's weight and therapeutic indication. Common side effects include bleeding, bruising at the injection site, and thrombocytopenia.
Nadroparin is contraindicated in patients with active bleeding, heparin-induced thrombocytopenia, or hypersensitivity to the active substance. Its use also requires careful monitoring to prevent hemorrhagic complications.
This medication is an effective option for the prevention and treatment of thromboembolic complications, helping to reduce the risk of severe cardiovascular events.
General data about FRAXODI 11400UI AFXa/0.6ml 11400 uiAXa / 0.6ml
- Substance:
- nadroparin
- Date of latest medicines list:
- 01-07-2013
- Product code:
- W42335002
- Concentration:
- 11400 uiAXa / 0.6ml
- Pharmaceutical form:
- solution for injection
- Quantity:
- 10
- Product type:
- Original
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Concentrations available for nadroparin
- 11400 uiAFXa/0.6ml
- 11400 uiAXa/0.6ml
- 15200 uiAFXa/0.8ml
- 15200 uiAXa/0.8ml
- 19000 uiAFXa/1ml
- 19000 uiAXa/ml
- 2850 ui AFXa/0.3ml
- 3800 ui AFXa/0.4ml
- 5700 ui AFXa/0.6ml
- 7600 ui AFXa/0.8ml
- 7600 ui AXa/0.8ml
- 9500 UI AFXa/1ml